This clinical trial is focused on studying a skin condition called Prurigo Nodularis. This condition is characterized by itchy, hard lumps on the skin. The trial will test the effectiveness and safety of a treatment using Ruxolitinib cream. Ruxolitinib is a medication applied directly to the skin, and it is being evaluated to see if it can help reduce the symptoms of Prurigo Nodularis.

The purpose of the study is to determine how well Ruxolitinib cream works in treating Prurigo Nodularis. Participants in the study will be randomly assigned to receive either the Ruxolitinib cream or a vehicle cream, which looks and feels like the Ruxolitinib cream but does not contain the active medication. This helps researchers compare the effects of the actual medication against a cream without the active ingredient. The study is designed to be “double-blind,” meaning neither the participants nor the researchers will know who is receiving the Ruxolitinib cream and who is receiving the vehicle cream, to ensure unbiased results.

Throughout the study, participants will apply the cream to their skin as directed and attend regular check-ups to monitor their progress. The study will last for several weeks, with key assessments at different points to evaluate improvements in symptoms. The main goal is to see if there is a significant reduction in itchiness and skin lesions after using the Ruxolitinib cream compared to the vehicle cream. Participants’ experiences and any changes in their condition will be carefully recorded to help determine the treatment’s effectiveness and safety.